File Name,Date of Petition,Date received,Identity of Submitting Entity,Representation Details,Cited Statutes or Regulations,FDA Action Commented On,Requested Action,Justification for Request
FDA-2024-P-0105-0001_Citizen_Petition_from_Graviti_Pharmaceuticals_Priv.pdf,"January 3, 2024",,Graviti Pharmaceuticals Private Limited,"Chandrika Lucki, Authorized US Agent, representing Graviti Pharmaceuticals Private Limited","21 C.F.R. §§ 10.25, 10.30, 314.122, 314.161; Sections 505(j) and 505(w) of the Federal Food, Drug, and Cosmetic Act","Discontinuation status of GLUCOTROL (glipizide) Tablets, NDA 017783, in the Orange Book","Request FDA to determine that Glucotrol Tablets, 5 mg and 10 mg, were not withdrawn for reasons of safety or effectiveness","Petitioner believes the discontinuation was due to commercial reasons, not safety or effectiveness; ANDAs for the same strength are active; no evidence of withdrawal due to safety or efficacy concerns"
FDA-2024-P-0109-0001_Citizen_Petition_from_Bausch_Lomb.pdf,"January 4, 2024",,Bausch + Lomb,"Kris Tucker, Senior VP, Global Regulatory Affairs, submitting on behalf of Bausch + Lomb","21 C.F.R. §§ 10.30, 10.31; Section 505(j) of the Federal Food, Drug, and Cosmetic Act",FDA's draft Product Specific Guidance (PSG) for ANDAs referencing Xipere (triamcinolone acetonide injectable suspension),"Request FDA to (1) refuse to receive or approve any ANDA referencing Xipere that uses a different injector unless in vivo and switching studies are included, and (2) revise the draft PSG to include such requirements and add syringeability and glide force to required comparisons",Xipere’s safety and efficacy depend critically on its proprietary SCS Microinjector; using a different injector without in vivo testing poses significant safety and efficacy risks. The current PSG does not adequately address this risk
FDA-2024-P-0227-0001_Suitability_Petition_from_Zydus_Pharmaceuticals__U.pdf,"January 10, 2024",,Zydus Pharmaceuticals (USA) Inc.,"Not representing another entity; petitioner is Zydus Pharmaceuticals (USA) Inc., a wholly owned subsidiary of Zydus Lifesciences Limited","505(j)(2)(C), 21 C.F.R. § 314.93, 21 C.F.R. §§ 10.20, 10.30, 21 C.F.R. § 25.31, 505B(a)(1)(A)(i)","Approval of an Abbreviated New Drug Application (ANDA) for a new strength of Methylene Blue Injection, USP, 5 mg/1 mL","Request that FDA determine Methylene Blue Injection, USP, 5 mg/1 mL, is suitable for submission in an ANDA despite differing in strength from the Reference Listed Drug (RLD)","The petitioner argues that the proposed change involves only total drug content, not concentration, maintaining the same active ingredient, dosage form, route of administration, and indications as the RLD. The new strength would provide dosing flexibility, reduce pharmaceutical waste, particularly in pediatrics, and does not raise questions of safety or effectiveness."
FDA-2024-P-0279-0001_Stay_of_Action_Petition_from_Hyman__Phelps___McNam.pdf,"January 11, 2024",,"Hyman, Phelps & McNamara, P.C.",Representing Nautilus Gloves LLC,"21 C.F.R. § 10.33(b), 21 C.F.R. § 10.35(b), 21 C.F.R. Part 16, 21 U.S.C. § 360c(e)","FDA’s December 12, 2023 rescission of the substantial equivalence determination for Nautilus Nitrile Exam Gloves (K210496)","Request that FDA (1) reconsider the rescission of the 510(k) clearance and (2) stay the rescission pending such reconsideration, allowing Nautilus to amend its submission with correct biocompatibility data","The rescission was based on an inadvertent clerical error by a testing lab that submitted data for the wrong product. The petitioner asserts that this does not constitute misconduct, that corrected valid test data is now available, and that the FDA acted without proper statutory authority or due process"
FDA-2024-P-0422-0001_Suitablity_Petition_from_Method_Pharmaceuticals__L.pdf,"January 11, 2024",,"Method Pharmaceuticals, LLC","Not representing another entity; the petitioner is Method Pharmaceuticals, LLC","505(j)(2)(C), 21 C.F.R. §§ 10.20, 10.30, 314.93, 25.31","FDA authorization to submit an ANDA for a dosage form different from the Reference Listed Drug (Folic Acid Tablets, 1 mg)","Request that FDA determine Folic Acid Oral Solution, 0.1 mg/mL and 1 mg/mL, is suitable for submission in an ANDA","The proposed oral solution differs only in dosage form from the approved tablet; it maintains the same active ingredient, route, and indication, offering improved dosing flexibility, especially for infants and patients requiring smaller maintenance doses"
FDA-2024-P-0425-0001_Suitability_Petition_from_RegCon_Solutions__LLC.pdf,"January 22, 2024",,"RegCon Solutions, LLC","Not representing another entity; the petitioner is RegCon Solutions, LLC","505(j), 21 C.F.R. §§ 10.20, 10.30, 25.31","Approval of an ANDA for Ziprasidone Mesylate Injection, 20 mg/mL, in a prefilled syringe as a change in dosage form from the Reference Listed Drug (GEODON lyophilized powder)","Request that FDA determine Ziprasidone Mesylate Injection, 20 mg/mL in a prefilled syringe (liquid formulation), is suitable for submission as an ANDA","The proposed product is Q1/Q2 identical to the RLD and differs only in being a ready-to-use liquid rather than a lyophilized powder. The change eliminates reconstitution steps without altering safety, efficacy, or dosing regimen, and aligns with existing label instructions"
FDA-2024-P-0427-0001_Suitability_Petition_from_DDReg_Pharma_Inc_.pdf,"January 17, 2024",,DDReg Pharma Inc.,Submitting on behalf of a prospective ANDA applicant (not named),"505(j)(2)(C), 21 C.F.R. §§ 314.93, 10.20, 10.30, 25.31",FDA determination of the Reference Listed Drug (RLD) for a progesterone-based pessary formulation,Request that FDA determine the RLD for an ANDA of a progesterone pessary formulation differing in dosage form and strength,"The proposed product uses the same active ingredient and route of administration as approved formulations, with the same indication. It poses no new safety or efficacy concerns, and PREA is not applicable because the use is for ART in infertile women, not pediatric patients"
FDA-2024-P-0435-0001_Suitability_Petition_from_Zydus_Pharmaceuticals__U.pdf,"January 22, 2024",,Zydus Pharmaceuticals (USA) Inc.,Zydus Pharmaceuticals (USA) Inc. is a wholly owned subsidiary of Zydus Lifesciences Limited,"505(j)(2)(C), 21 C.F.R. § 314.93, 21 C.F.R. §§ 10.20 and 10.30, 21 C.F.R. § 25.31, 505B(a)(1)(A)(i)",Establishment of a reference listed drug with a new strength for ANDA submission,"Determine that Pimavanserin Tablets, 34 mg is suitable for submission in an ANDA as a new strength of the RLD","The petitioner argues that the proposed 34 mg tablet strength is consistent with the recommended daily dose listed in the prescribing information of the RLD but is not currently available in tablet form. Approving the petition would provide physicians and patients greater flexibility without requiring a change in dosage form (e.g., from tablets to capsules). The change does not raise new questions of safety or efficacy, and pediatric assessment requirements under PREA do not apply since the petition is only for a new strength."
FDA-2024-P-0521-0001_Citizen_Petition_from_Kasowitz_Benson_Torres_LLP_o.pdf,"January 24, 2024",,Kasowitz Benson Torres LLP,Representing Adventapharma DWC LLC,"21 C.F.R. §§ 10.25, 10.30, 10.31, 314.70; Federal Food, Drug, and Cosmetic Act",Approval and continued marketing of Enoxaparin Sodium Injection (ANDA No. 077857) manufactured by Shenzhen Techdow Pharmaceutical Co. Ltd and supplied by Sandoz Inc.,Request that FDA investigate and take appropriate action regarding the safety of the Sandoz Enoxaparin Sodium Injection due to concerns over inaccurate dosing in prefilled syringes,"The petitioner claims that the Sandoz product poses a patient safety risk due to the possibility of inaccurate dosing associated with demarcations on prefilled syringes, potentially leading to unsafe administration of enoxaparin sodium"
FDA-2024-P-0522-0001_Citizen_Petition_from_Kasowitz_Benson_Torres_LLP_o.pdf,"January 24, 2024",,Kasowitz Benson Torres LLP,Representing Adventapharma DWC LLC,"21 C.F.R. §§ 10.25, 10.30, 10.31, 314.70; Federal Food, Drug, and Cosmetic Act","Approval and continued marketing of Enoxaparin Sodium Injection (ANDA No. 205660) manufactured by Shenzhen Techdow Pharmaceutical Co., Ltd. and supplied for NorthStar Rx LLC",Request that FDA investigate and take appropriate actions regarding the safety of the NorthStar Enoxaparin Sodium Injection due to potential issues with inaccurate dosing in prefilled syringes,"The petitioner asserts that blocked or obscured syringe demarcations may result in unclear dosing, posing significant safety risks to patients using the NorthStar product"
FDA-2024-P-0526-0001_Suitability_Petition_from_Lupin__Inc_.pdf,"January 26, 2024",,Lupin Inc.,Not representing another entity; the petitioner is Lupin Inc.,"505(j)(2)(C), 21 C.F.R. §§ 10.20, 10.30, 25.31","FDA authorization to submit an ANDA for Apixaban Oral Suspension, 1.25 mg/mL, differing in dosage form from the listed drug ELIQUIS Tablets","Request that FDA determine Apixaban Oral Suspension, 1.25 mg/mL, is suitable for submission in an ANDA as a change in dosage form from the RLD","The oral suspension offers equivalent dosing to ELIQUIS tablets (2.5 mg and 5 mg) and supports patients with dysphagia. The formulation improves convenience, ensures dosing accuracy, and reduces burden in assisted care settings. A bioequivalence study will be submitted, and a waiver of PREA requirements is requested based on FDA precedent and availability of alternative pediatric formulations"
FDA-2024-P-0545-0001_Suitability_Petition_from_HYMAN__PHELPS___MCNAMARA.pdf,"January 29, 2024",,"Hyman, Phelps & McNamara, P.C.",Representing an unnamed client,"505(j)(2)(C), 21 C.F.R. §§ 314.93, 10.20, 10.30, 25.31",Authorization for submission of an ANDA for a new dosage form and strength of buspirone hydrochloride,"Request that FDA determine Buspirone HCl Oral Solution, 2 mg/mL, is suitable for submission in an ANDA as a change from the RLD BUSPAR Tablets",The proposed oral solution offers flexibility for individualized dosing and is consistent with the RLD's dosing guidance. FDA previously determined that BUSPAR Tablets were not withdrawn for safety or effectiveness. A full PREA waiver is requested due to lack of therapeutic benefit in pediatric populations and availability of better alternatives such as LEXAPRO
FDA-2024-P-0666-0001_Petition_for_Stay_of_Action_from_Royal_Diamond_Imp.pdf,"January 26, 2024",,"Royal Diamond Imports, Inc.","Not representing another entity; petitioner is Royal Diamond Imports, Inc.","21 C.F.R. § 10.35, 21 C.F.R. § 10.75; Administrative Procedure Act","FDA’s December 29, 2023 Marketing Denial Order (MDO) for ENDS products under bundled PMTAs STN PM0004990",Request that FDA stay the effective date of the Marketing Denial Order for an indefinite period,"The petitioner argues that FDA violated the Administrative Procedure Act by acting arbitrarily and without proper notice, including failure to notify that scientific review had begun. Given the ongoing and lengthy administrative appeals process, a stay is necessary to prevent irreversible harm"
FDA-2024-P-0667-0001_Suitability_Petition_from_Lachman_Consultant_Servi.pdf,"February 5, 2024",,"Lachman Consultant Services, Inc.",Submitting on behalf of a client (identity not disclosed),"505(j)(2)(C), 21 C.F.R. §§ 10.20, 10.30, 314.93, 25.31",Suitability of a new strength (3 g/100 mL) of Magnesium Sulfate in Water for Injection for submission in an ANDA,"Request that FDA determine Magnesium Sulfate in Water for Injection, 3 g/100 mL (30 mg/mL), is suitable for submission in an ANDA","The proposed strength fills a gap between currently available ready-to-administer doses (1 g, 2 g, 4 g), aligning with clinical practices that often use 3 g doses. The formulation change only affects total drug content and not concentration, dosage form, route of administration, or indications. The change could reduce waste and improve dosing efficiency. PREA does not apply as the change involves only strength, not formulation or indication."
FDA-2024-P-0761-0001_Suitability_Petition_from_RegCon_Solutions_LLC.pdf,"February 21, 2024",,"Pharmobedient Consulting, LLC","Submitted by Pharmobedient Consulting, LLC; representing an unspecified client","505(j), 21 C.F.R. §§ 10.25(a), 10.30, 314.122, 314.161, 314.162, 25.31, 25.40","Status of TAVIST (Clemastine Fumarate) Tablets, 2.68 mg under NDA 017661 as discontinued in the Orange Book","Request that FDA determine whether TAVIST (Clemastine Fumarate) Tablets, 2.68 mg was withdrawn from sale for reasons of safety or effectiveness","Petitioner asserts that TAVIST was likely discontinued for commercial reasons, not safety or efficacy, and there is no known evidence suggesting safety or effectiveness concerns. The request is to allow its continued citation as a Reference Listed Drug (RLD) in ANDAs"
FDA-2024-P-0805-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,"February 13, 2024",,"Hyman, Phelps & McNamara, P.C.",Representing an unnamed client,"505(j), 505(w); 21 C.F.R. §§ 10.25, 10.30, 314.122, 314.161, 314.162, 25.31",Discontinuation status of Fentanyl Citrate Injection (NDA 215870) listed in the Orange Book,"Request that FDA determine whether Fentanyl Citrate Injection, EQ 2.5 mg base/50 mL and EQ 5 mg base/100 mL, was withdrawn for reasons of safety or effectiveness",Petitioner asserts there is no known evidence suggesting safety or efficacy concerns; the product was likely discontinued for commercial reasons and should remain available as a reference listed drug for ANDA submissions
FDA-2024-P-0806-0001_Citizen_Petition_from_Center_for_Science_in_the_Pu.pdf,"February 12, 2024",,"Center for Science in the Public Interest (CSPI), American Public Health Association, Consumer Federation of America, and Consumer Reports",Not representing another entity; these are the submitting entities themselves,"5 U.S.C. § 553(e), 21 U.S.C. § 343, 21 C.F.R. § 101.11(a), 21 C.F.R. § 10.30",FDA's December 2023 draft guidance that encourages voluntary menu labeling on third-party platforms (TPPs),Request that FDA issue final guidance clarifying that its existing menu labeling regulations apply to menus from Covered Establishments posted and/or maintained on TPPs,"Consumers ordering from TPPs currently lack consistent access to calorie and nutrition information required under the ACA. Voluntary measures have proven insufficient, and the law already supports extending these requirements to menus on TPPs when controlled by Covered Establishments. Mandatory labeling would promote informed choices, improve public health, and align with FDA’s regulatory framework."
FDA-2024-P-0827-0001_Citizen_Petition_from_Aurobindo_Pharma_USA__Inc__.pdf,"February 14, 2024",,"Aurobindo Pharma USA, Inc.","Blessy Johns, US Agent for Aurobindo Pharma Limited","505(j), 21 C.F.R. §§ 10.25(a), 10.30, 314.122, 314.161, 314.162, 25.31(a), 25.15(d)","Discontinuation status of DUEXIS (Ibuprofen and Famotidine) Tablets, 800 mg and 26.6 mg, NDA 022519, in the Orange Book","Request that FDA determine whether DUEXIS (Ibuprofen and Famotidine) Tablets, 800 mg and 26.6 mg, was withdrawn for reasons of safety or effectiveness",Petitioner notes that the product appears in the discontinued section of the Orange Book and requests FDA's determination to clarify whether the withdrawal was due to safety or efficacy concerns. This determination is needed before an ANDA referring to the listed drug can be approved
FDA-2024-P-0889-0001_Suitability_Petition_from_Aurora_Pharmaceutical__I.pdf,"February 19, 2024",,"Aurora Pharmaceutical, Inc.","Not representing another entity; petitioner is Aurora Pharmaceutical, Inc.","Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. §§ 25.15, 25.21, 25.30(h)",Approval of an abbreviated new animal drug application (ANADA) for Afoxolaner Oral Solution 4.56% w/v as a different dosage form than the reference listed Nexgard® (afoxolaner) Chewables under NADA 141-406,Request that FDA determine Afoxolaner Oral Solution 4.56% w/v is suitable for submission as an ANADA despite being a different dosage form than the reference listed drug,"The proposed product contains the same active ingredient, route of administration, indications, and dosing regimen as the RLD but is offered as a liquid solution for dogs unable to consume chewables due to allergies or palatability issues. All excipients are used in other approved oral canine products. Packaging and labeling will be designed to ensure accurate dosing and safety"
FDA-2024-P-0973-0001_Citizen_Petition_from_Robin_Webb.pdf,"March 27, 2024",,Robin Webb,Not Mentioned,21 C.F.R. 10.30,Labeling of photosensitivity associated with sulfonamide medications,"Caution, Free Radical Risk'","The petitioner provides a detailed explanation of how sulfonamide moiety medications absorb UV radiation leading to free radical formation, which in turn may generate reactive oxygen species (ROS) causing harm to various organs. The petitioner argues that this mechanism explains observed adverse effects such as skin darkening, exacerbation of conditions like lichen planus, and organ damage. Cases submitted to FDA MedWatch reportedly support this claim, showing improvement when patients switched to non-sulfonamide alternatives."
FDA-2024-P-1030-0001_Citizen_Petition_from_William_D__Drake___Redacted.pdf,"February 28, 2024",,William D. Drake,Not Mentioned,"907(a)(1)(B) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. § 10.30",Use and distribution of Certified 1R6F Kentucky Reference Cigarettes (and related variants) for research by FDA and its oversight of pesticide contamination in those products,"Request that FDA test and publicly disclose any pesticide residues found in Certified 1R6F and other Kentucky Reference Cigarettes distributed for research, notify all past and future recipients, and assess whether such residues reflect the broader U.S. commercial tobacco product supply","Petitioner argues that reference cigarettes used in tobacco research may be contaminated with unreported pesticide residues, potentially skewing decades of research data. Without testing and transparency, the validity of past and current tobacco-related research is compromised, and the public may unknowingly face risks from such contaminants. Petition also highlights the lack of FDA testing, calls for alignment with HPHC policies, and cites historical and international findings to support the need for urgent assessment."
FDA-2024-P-1058-0001_Citizen_Petition_from_Aimed_Alliance.pdf,"March 1, 2024",,Aimed Alliance,Not representing another entity; petitioner is Aimed Alliance,"21 C.F.R. § 10.30, 21 C.F.R. § 10.115, FD&C Act § 804, 21 C.F.R. § 25.30",Importation practices under alternative funding programs and the lack of clear FDA guidance on their legality,"Request that FDA issue a guidance document clarifying the legality of drug importation practices by third-party companies working with employer-sponsored health plans, including whether such entities can mandate or facilitate importation of prescription drugs on behalf of consumers, and how to report such practices","Petitioner argues that alternative funding programs are importing unapproved and misbranded drugs from foreign pharmacies on behalf of consumers, bypassing legal pathways such as personal importation and Section 804 programs. The lack of clear FDA guidance has enabled these programs to continue unchecked, potentially exposing consumers to serious health risks. Clarifying FDA’s stance would protect consumers, promote transparency, and restore regulatory accountability."
FDA-2024-P-1130-0001_Citizen_Petition_from_Valisure.pdf,"March 5, 2024",,"Valisure, LLC",Not Applicable,"21 U.S.C. §§ 331, 352, 355, 372, 374, 375; 21 C.F.R. §§ 10.20, 10.30","Sale and regulation of benzoyl peroxide (BPO) drug products, particularly in relation to benzene contamination","Issue a regulation, revise industry guidance, request a recall, and suspend sales of benzoyl peroxide products; conduct investigations; and undertake several regulatory and public health actions as detailed in the petition","Valisure detected high levels of benzene, a known human carcinogen, forming in benzoyl peroxide products when stored at elevated temperatures. They argue this poses a serious public health risk, referencing epidemiological data, FDA standards, and prior regulatory actions on contaminants such as NDMA. They highlight that BPO decomposes into benzene and request urgent regulatory action including recalls, guidance revisions, public disclosures, and stricter testing requirements."
FDA-2024-P-1131-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC.pdf,"March 5, 2024",,"Fresenius Kabi USA, LLC","Not representing another entity; the petitioner is Fresenius Kabi USA, LLC","21 C.F.R. § 10.30, 21 C.F.R. § 314.161, 21 C.F.R. § 314.162, 21 C.F.R. § 25.31",Determination of whether Diltiazem Hydrochloride in Dextrose Injection (NDA 215252) has been withdrawn for safety or effectiveness reasons,Request that FDA determine whether Diltiazem Hydrochloride in Dextrose Injection 125 mg/125 mL and 250 mg/250 mL was withdrawn for safety or efficacy reasons,"The drug product now appears in the 'Discontinued Section' of the Orange Book. Petitioner seeks confirmation that it was not withdrawn for reasons of safety or effectiveness, which is a requirement for ANDA referencing under 21 C.F.R. § 314.161. The petition supports this by noting such withdrawals can occur for business or other non-safety-related reasons."
FDA-2024-P-1223-0001_Citizen_Petition_from_Charles_Ludlam_Redacted.pdf,"March 5, 2024",,Charles Ludlam,Not Mentioned,21 C.F.R. § 10.30,Labeling and clinical evaluation policies for Mounjaro/Zepbound and Ozempic/Wegovy,"Request that FDA (1) require additional clinical trials on lean muscle mass loss, goal weight setting, and weight maintenance; and (2) revise product labels to include findings and recommendations related to these issues","The petitioner argues that current labels lack sufficient information about risks of lean muscle mass (LMM) loss, guidance on setting ideal goal weight, and strategies for maintaining weight loss. He cites clinical trial data showing substantial LMM loss and expresses concern over off-label use, especially in elderly populations already at risk of sarcopenia. The petition calls for enhanced labeling and additional clinical trials to provide more comprehensive safety and usage guidance."
FDA-2024-P-1378-0001_Citizen_Petition_from_Organon_USA__LLC_Redacted.pdf,"March 1, 2024",,"Organon USA, LLC","Not representing another entity; the petitioner is Organon USA, LLC","Section 505 of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. § 10.30",FDA review and approval of ANDAs referencing NEXPLANON (etonogestrel implant) as the reference listed drug,"Request that FDA require ANDA applicants to (a) demonstrate bioequivalence through a full-duration in vivo pharmacokinetic study or a validated IVIVC model, and (b) conduct comparative dissolution testing (f2 test) for their generic etonogestrel implant","Organon argues that due to NEXPLANON's long-acting nature and complex drug release profile, abbreviated methods may not ensure therapeutic equivalence. Full-duration BE studies or IVIVC models are necessary to protect patient safety and ensure consistent contraceptive efficacy over the entire approved in-use period."
FDA-2024-P-1379-0001_Citizen_Petition_from_Physicians_Committee_for_Res.pdf,"March 19, 2024",,Physicians Committee for Responsible Medicine,Not Mentioned,21 C.F.R. § 10.30,"FDA's March 1, 2024, letter of enforcement discretion permitting qualified health claims about yogurt and reduced risk of type 2 diabetes","Withdraw the March 1, 2024, letter of enforcement discretion and cease exercising enforcement discretion for qualified health claims about yogurt and reduced risk of type 2 diabetes","The petitioner argues that the qualified health claims are not supported by sufficient scientific evidence. Most studies cited in the original petition had methodological limitations, lacked randomized controlled trials, and showed inconsistent results. The claims may mislead consumers into believing yogurt is effective in diabetes prevention, possibly at the expense of more effective, evidence-based lifestyle changes like adopting a plant-based diet."
FDA-2024-P-1380-0001_Citizen_Petition_from_Kohl_Harrington___Redacted.pdf,"March 4, 2024",,Kohl Harrington,Not Mentioned,"5 U.S.C. § 552; 21 C.F.R. §§ 10.30(b), 25.30, 25.34",FDA’s handling and lack of public disclosure regarding FOIA request 2020-5368,Request that FDA publish all records and response letters related to FOIA request 2020-5368 in the FDA FOIA Reading Room,"Petitioner argues that under FOIA (5 U.S.C. § 552(a)(2)(D)), records that have been requested three or more times must be made publicly available. The specific FOIA request relates to reports of illness from A+ Answers Straight Beef Formula for Dogs. The FDA reportedly responded with no records found, which the petitioner believes has broader implications regarding FDA-CVM's interpretation and communication of regulatory standards on raw pet food and Salmonella contamination."
FDA-2024-P-1403-0001_Suitability_Petition_from_Pharmobedient_Consulting.pdf,"March 20, 2024",,"Pharmobedient Consulting, LLC","Not representing another entity; the petitioner is Pharmobedient Consulting, LLC","505(j)(2)(C) of the FD&C Act; 21 C.F.R. §§ 10.20, 10.30, 314.93, 25.31","Approval of an ANDA for Dantrolene Sodium Orally Disintegrating Tablets (ODT), a different dosage form from the RLD Dantrium Capsules","Request that FDA determine Dantrolene Sodium ODT (25 mg, 50 mg, 100 mg) is suitable for submission in an ANDA","Petitioner argues that the proposed ODT formulation improves patient adherence, especially for elderly or dysphagic individuals, by allowing administration without water. The product contains the same active ingredient, route of administration, and strengths as the RLD. The petitioner also requests a pediatric study waiver, asserting no added risk to pediatric populations and no need for new efficacy/safety data."
FDA-2024-P-1440-0001_Citizen_Petition_from_pH_D_Feminine_Health__LLC.pdf,"March 22, 2024",,"pH-D Feminine Health, LLC and Vireo Systems, Inc.",Not representing another entity; petitioners are pH-D Feminine Health and Vireo Systems themselves,"21 C.F.R. §§ 10.20, 10.30; 21 U.S.C. § 321(i), § 321(g); 21 C.F.R. § 201.128; 5 U.S.C. § 551(5); 21 C.F.R. § 10.115",FDA's classification of over-the-counter (OTC) vaginal suppositories containing boric acid marketed solely with deodorant or odor-reduction claims,"Request that FDA issue guidance stating these products are 'cosmetics' and not also 'drugs.' Alternatively, if deemed 'drugs,' request (1) formal regulation classifying them as such, and (2) an enforcement discretion policy until regulation is finalized",Petitioners argue that prior FDA statements in the 1983 and 1994 Federal Register notices create a reasonable expectation that such products are cosmetics. They claim boric acid has never been approved as a drug ingredient and that current deodorant-only claims should classify the products as cosmetics under the FDCA. They further argue that reclassification to 'drugs' would require formal rulemaking under the Administrative Procedure Act and FDA Good Guidance Practices. The petition seeks clarity and regulatory consistency to prevent disruption to lawful market activities.
FDA-2024-P-1441-0001_Suitability_Petition_from_Epic_Pharma__LLC.pdf,"March 22, 2024",,"Epic Pharma, LLC","Not representing another entity; petitioner is Epic Pharma, LLC","505(j)(2)(C) of the FD&C Act; 21 C.F.R. §§ 10.20, 10.30, 314.93, 25.31",Approval of an ANDA for Leucovorin Calcium Injection in new strengths and dosage form different from the RLD,"Request that FDA determine that Leucovorin Calcium Injection (preservative-free, sterile solution) in strengths of 200 mg(base)/20 mL and 350 mg(base)/35 mL, and in a ready-to-use dosage form, is suitable for submission in an ANDA","Petitioner argues that the proposed product maintains the same concentration and labeling as the reference standards, with changes only to total drug content and dosage form (from lyophilized powder to ready-to-use solution). The change offers clinical convenience without raising safety or efficacy concerns. The petition also requests a waiver of PREA requirements, asserting the product is unlikely to benefit or be widely used by pediatric patients."
FDA-2024-P-1483-0001_Suitability_Petition_from_Hyman_Phelps_and_McNamar.pdf,"March 28, 2024",,"Hyman, Phelps & McNamara, P.C.","Hyman, Phelps & McNamara, P.C. is representing Fresenius Kabi USA, LLC","Section 505(j)(2)(C) of the FD&C Act; 21 C.F.R. §§ 10.20, 10.30, 314.93",Approval of an ANDA for a different strength and dosage form of Sugammadex Injection compared to the RLD,"Request that FDA determine that Sugammadex Injection, 400 mg/8 mL (50 mg/mL), in a single-dose vial, is suitable for submission via an ANDA referencing Bridion (Sugammadex) Injection, 200 mg/2 mL and 500 mg/5 mL","Petitioner argues the proposed product contains the same active ingredient, route of administration, and concentration (50 mg/mL) as the RLD, with only a difference in strength and container volume. The change offers logistical and clinical convenience without affecting safety or efficacy. The petitioner also requests a waiver of pediatric study requirements under PREA, asserting no meaningful pediatric use."
FDA-2024-P-1570-0001_Citizen_Petition_from_Bongards_Premium_Cheese.pdf,"March 26, 2024",,Bongards Premium Cheese,Not representing another entity; petitioner is Bongards Premium Cheese,"21 C.F.R. § 10.30; 21 C.F.R. §§ 133.169, 133.173, 133.179","Standards of Identity for Pasteurized Process Cheese, Pasteurized Process Cheese Food, and Pasteurized Process Cheese Spread",Request that FDA amend the standards of identity for the listed cheese categories to allow the use of extra virgin olive oil as an anti-sticking agent in cheese slices,"Petitioner argues that incorporating extra virgin olive oil as an anti-sticking agent will maintain product integrity during manufacturing and packaging while aligning with consumer preferences for recognizable and clean-label ingredients. This change would not alter the fundamental nature, nutritional value, or characteristics of the standardized cheese products."
FDA-2024-P-1715-0001_Citizen_Petition_from_AbbVie_Inc_.pdf,"April 3, 2024",,AbbVie Inc.,Not representing another entity; AbbVie is the petitioner and product sponsor.,"21 C.F.R. § 10.30, Federal Food, Drug, and Cosmetic Act (FDCA), Public Health Service Act (PHSA), Biologics Price Competition and Innovation Act (BPCIA), 21 C.F.R. § 312.7(a), FDCA § 502(a), 42 U.S.C. § 262(j)","Proliferation and marketing of unlicensed desiccated thyroid extract (DTE) products without INDs or BLAs, and associated promotional practices",FDA should prohibit manufacturers lacking active INDs and robust clinical development programs from commercializing unlicensed DTE products and should stop the promotion of unlicensed products with false and misleading claims,"The petitioner argues that the influx of unlicensed DTE products, lacking regulatory oversight, poses a public health risk due to narrow therapeutic margins and substandard manufacturing. AbbVie emphasizes the precedent set by FDA in similar historical contexts (e.g., PEPs and levothyroxine sodium), the necessity of IND oversight, misleading promotional practices, and confusion caused by classification systems falsely implying therapeutic equivalence among unapproved products"
FDA-2024-P-1716-0001_Suitability_Petition_from_Aurora_Pharmaceutical__I.pdf,"April 3, 2024",,"Aurora Pharmaceutical, Inc.","Not representing another entity; the petitioner is Aurora Pharmaceutical, Inc.","Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. §§ 10.20, 10.30, 25.30(h)",Approval of an ANADA for a generic meloxicam oral solution differing from the RLNAD in dosage form and strength,"Request that FDA determine that a generic meloxicam oral solution, 5 mg/mL, is suitable for submission via an ANADA referencing Metacam (meloxicam) Oral Suspension (0.5 mg/mL and 1.5 mg/mL)","Aurora seeks approval for a higher strength solution (5 mg/mL) to improve dosing convenience and precision for dogs over 10 lbs. They argue this change reduces volume, enhances dose compliance, and does not alter the recommended dosage or indications. Aurora also notes there are no listed patents or marketing exclusivities for the RLNAD and that a similar petition for dosage form change was previously approved."
FDA-2024-P-1717-0001_Citizen_Petition_from_Kohl_Harrington_Redacted.pdf,"April 4, 2024",,Kohl Harrington,Not Mentioned,"5 U.S.C. § 552; 21 C.F.R. §§ 10.30(b), 25.30, 25.34",FDA’s failure to publish the final document for the CVM Key Initiative Plan 2019-2020 on the FDA FOIA Reading Room website,Request that FDA-CVM comply with FOIA law and post all documents requested through various FOIA requests pertaining to the final document for the CVM Key Initiative Plan 2019-2020 on the public FDA FOIA Reading Room website,Petitioner asserts that the final document for the CVM Key Initiative Plan 2019-2020 has been requested three or more times through FOIA and thus must be publicly disclosed under 5 U.S.C. § 552(a)(2)(D). The petition seeks compliance with this FOIA requirement by making the document available to the public electronically.
FDA-2024-P-1788-0001_Suitability_Petition_from_Pharmobedient_Consulting.pdf,"April 10, 2024",,"Pharmobedient Consulting, LLC","Not representing another entity; the petitioner is Pharmobedient Consulting, LLC","505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. §§ 10.20, 10.30, 314.93, 25.31",Suitability of an ANDA submission for a different dosage strength of Carbinoxamine Maleate Tablets compared to the Reference Listed Drug (RLD),"Request that FDA determine that Carbinoxamine Maleate Tablets, 2 mg (unscored), is suitable for submission in an ANDA referencing CLISTIN (Carbinoxamine Maleate) 4 mg tablets","Petitioner argues that the change in dosage strength from 4 mg to 2 mg is consistent with dosing instructions for the RLD and does not raise questions of safety or efficacy. The proposed 2 mg strength provides greater dosing flexibility, particularly for pediatric use, and will be formulated to meet all quality and regulatory standards including bioequivalence to the RS."
FDA-2024-P-1810-0001_Suitability_Petition_from_Pharmobedient_Consulting.pdf,"April 10, 2024",,"Pharmobedient Consulting, LLC","Pharmobedient Consulting, LLC is submitting the petition on behalf of a client, but the represented entity is not named","505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. §§ 10.20, 10.30, 314.93; 21 C.F.R. § 25.31(a)",Approval of an ANDA for a new strength of Amphotericin B Liposome for Injection differing from the reference listed drug,"Request that FDA determine Amphotericin B Liposome for Injection, 100 mg/vial lyophilized powder, is suitable for submission in an ANDA referencing AmBisome (50 mg/vial)","Petitioner states that the only change from the reference listed drug is the total drug content (from 50 mg to 100 mg), with no change in concentration. This change would reduce the number of vials needed per dose, potentially lowering pharmaceutical waste and improving dosing efficiency, especially for larger patients. Reconstitution instructions are adjusted accordingly. No questions of safety or efficacy are raised by this change."
FDA-2024-P-1870-0001_Suitability_Petition_from_Newcastle_Bioscience__LL.pdf,"April 15, 2024",,Newcastle Bioscience LLC,Not representing another entity; submitted directly by Newcastle Bioscience LLC,"505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. §§ 10.30, 314.94(a)(8)(iv), 25.31",Suitability of an ANDA for a new dosage form (orally disintegrating tablets) and strength (15 mg) of escitalopram oxalate compared to the RLD Lexapro Tablets,"Request that the FDA declare escitalopram oxalate orally disintegrating tablets in 5 mg, 10 mg, 15 mg, and 20 mg strengths suitable for submission as an ANDA referencing Lexapro Tablets","The petitioner argues that the proposed dosage form (ODT) facilitates easier administration for patients with dysphagia and provides flexibility in dosing, particularly with the 15 mg strength which aligns with approved labeling but is not currently available. The change does not affect safety or efficacy, and similar changes have been previously approved by FDA. A full waiver of pediatric study requirements is also requested based on precedent and current data."
FDA-2024-P-1871-0001_Citizen_Petition_from_Advanced_Accelerator_Applica.pdf,"April 12, 2024",,"Advanced Accelerator Applications USA, Inc.",The petitioner is submitting on behalf of itself; it is identified as a Novartis Company.,21 USC 355; 21 CFR 10.30; 21 CFR 314.92(a)(1); 21 CFR 314.127(a)(4)(i); 21 USC 355(d); 21 USC 355(j)(4)(A); 21 CFR 314.54; 21 CFR 314.94(a)(9)(iii); 21 USC 505(b)(2); 21 USC 355(j)(2)(A)(iii)-(v); 21 CFR 320.22(b); 21 CFR 212.1,Approval of any ANDA under section 505(j) or NDA under section 505(b)(2) that references and relies on Lutathera (lutetium Lu 177 dotatate).,"FDA must require that any proposed generic or 505(b)(2) version of Lutathera demonstrate pharmaceutical equivalence—including same Specific Activity, Total Activity, Volumetric Activity, and total mass of ligand—as well as ensure individualized patient doses (fill volumes of 20.5–25.0 mL) and identical labeling.","Lutathera is a dynamic radioligand therapeutic whose clinical effect depends not only on radioactivity levels (Volumetric and Total Activity) but also on the Specific Activity and the mass ratio of labeled to unlabeled ligand. Differences in these variables may alter biodistribution and safety profiles, making simple equivalence claims insufficient without tailored analytical assessments. Therefore, FDA should refrain from approving any application unless these factors are demonstrated to be equivalent."
FDA-2024-P-1913-0001_Citizen_Petition_from_Amivas__Inc_.pdf,"April 17, 2024",,"Amivas, Inc.",Fast Track Drugs and Biologics LLC is acting as the sponsor’s representative,"505(j)(2)(C) of the FD&C Act; 21 C.F.R. §§ 10.20, 10.30, 314.93; 21 C.F.R. § 25.31(a)",Suitability of an ANDA for a methylene blue injection product with a different strength than the RLD ProvayBlue®,"Request that FDA permit submission of an ANDA for Methylene Blue Injection, USP (10 mg/mL, 50 mg/5 mL vial), differing in concentration from the RLD ProvayBlue® (5 mg/mL)","The petitioner argues that the proposed drug product has the same active ingredient, route of administration (IV), dosage form, excipient (water), dilution procedure, and therapeutic effect as the RLD. The only change is the concentration per mL, not the total dose per vial. The change does not raise concerns for safety, efficacy, or bioequivalence, and similar products have been authorized in other countries."
FDA-2024-P-1916-0001_Citizen_Petition_from_Association_for_Truth_in_Pet.pdf,"April 17, 2024",,Association for Truth in Pet Food,Susan Thixton submitted the petition on behalf of the Association for Truth in Pet Food and pet food consumers,21 C.F.R. §§ 10.20 and 10.30,Lack of public updates from FDA Center for Veterinary Medicine (CVM) on ongoing pet food-related illnesses and deaths,"Request FDA CVM to issue public updates regarding its investigation into pet food products associated with bloody vomiting, diarrhea, seizures, and pet deaths, including details such as number of reports, symptoms, testing conducted, and brands involved","Over 2,600 pet illness cases and 500+ pet deaths have been reported by consumers since December 2023, without FDA response or public updates; previous FDA actions on similar cases (e.g., applesauce, jerky treats, canine heart disease) included public notifications even without confirmed causes; transparency is needed to protect both animal and human health"
FDA-2024-P-1937-0001_Citizen_Petition_from_Kohl_Harrington_Redacted.pdf,"April 18, 2024",,Kohl Harrington,Not representing another entity; submitted as an individual,"5 U.S.C. § 552; 21 C.F.R. §§ 10.30(b), 25.30, and 25.34",Failure of FDA-CVM to publicly disclose calendar records requested under FOIA,Request FDA-CVM to publish in the FDA FOIA Reading Room all documents related to calendar records of FDA-CVM employee William T. Flynn for the period 01/01/2024 to 02/29/2024,"Petitioner asserts that the requested calendar records meet the legal threshold under FOIA (5 U.S.C. § 552(a)(2)(D)) for mandatory public disclosure because they have been requested three or more times. Therefore, FDA-CVM is legally obligated to make them available in the public FOIA Reading Room."
FDA-2024-P-1960-0001_Citizen_Petition_from_Kohl_Harrington_Redacted.pdf,"April 20, 2024",,Kohl Harrington,Not representing another entity; submitted as an individual,"5 U.S.C. § 552; 21 C.F.R. §§ 10.30(b), 25.30, 25.34","FDA-CVM's failure to publicly disclose inspection reports and documents related to Lystn, LLC (Answer Pet Food), despite multiple FOIA requests","FDA-CVM must publish in the FDA FOIA Reading Room all inspection reports and related documents for Lystn, LLC (Answer Pet Food), covering the period from January 1, 2023 to December 31, 2023","Under FOIA (5 U.S.C. § 552(a)(2)(D)), records that have been requested three or more times must be publicly disclosed. The petitioner asserts that the Lystn, LLC documents meet this threshold and therefore must be made publicly available by FDA-CVM"
FDA-2024-P-1988-0001_Citizen_Petition_from_HealthyWomen.pdf,"April 22, 2024",,HealthyWomen,Not Mentioned,"21 C.F.R. § 10.30, 21 C.F.R. §§ 200.5 and 201.56-57, 21 U.S.C. § 355(o)(4)",Labeling of fenofibrate drugs and communication of cardiovascular risk benefit misinformation,Revise fenofibrate labeling to clarify the lack of cardiovascular benefit and include new safety data; require DHCP letters and a Drug Safety Communication,"Due to persistent misperceptions among healthcare providers that fenofibrates reduce cardiovascular risk—despite multiple clinical trials (FIELD, ACCORD, PROMINENT) showing no such benefit—along with associated risks (e.g., VTE, rhabdomyolysis), the petitioner urges the FDA to revise labeling and issue communications to ensure patients are not improperly prescribed fenofibrates, forgo effective treatments, or face unnecessary risks and costs."
FDA-2024-P-2084-0001_Citizen_Petition_from_People_for_the_Ethical_Treat.pdf,"April 25, 2024",,People for the Ethical Treatment of Animals (PETA),"Ashely Monti, Legal Fellow, PETA Foundation; no indication of representing another entity","5 U.S.C. § 553(e); 21 C.F.R. § 10.30; 21 U.S.C. §§ 321(n), 343(a)(1), 371(a); 21 C.F.R. § 101.17",FDA labeling regulations for milk and other dairy products lacking cancer risk disclosures,"Linked to Increased Risk of Prostate, Breast, and Ovarian Cancer.'","Numerous scientific studies suggest a strong association between dairy consumption and increased risks of prostate, breast, and ovarian cancers, with mechanisms involving IGF-1 levels, estrogen content in milk, and galactose toxicity; such information is material for consumer health decisions and consistent with FDA precedent for labeling in the presence of serious health risks."
FDA-2024-P-2085-0001_Suitability_Petition_from_Hospira__Inc_.pdf,"April 2, 2024",,Hospira Inc.,Not Mentioned,"Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act; 21 C.F.R. §§ 314.93, 10.20, 10.30",Prior denial of a suitability petition (Docket No. FDA-2023-P-4334) based on the existence of an NDA-approved version of the proposed drug strength,"FDA approval to submit an ANDA for Vancomycin Hydrochloride for Injection, USP, ADD-Vantage® Vial, 1.25 grams (base)/vial as an additional strength","The proposed product is identical in all respects to the reference listed drug except for strength. It addresses dosing needs for patients requiring more than 1 gram per dose, and differs qualitatively from the NDA-approved 1.25 g version (Mylan NDA 209481) due to the inclusion of pH-adjusting excipients, thereby justifying a separate ANDA submission."
FDA-2024-P-2148-0001_Citizen_Petition_from_Neşe_Devenot_Redacted.pdf,4/28/24,,"Neşe Devenot, PhD, Senior Lecturer, Johns Hopkins University",Not Mentioned,21 CFR 14.29; 21 CFR 312.32(a); 45 CFR 46.103(a); 45 CFR 46.103(b)(5),FDA's planned advisory committee meeting on the Lykos Therapeutics MDMA-Assisted Therapy New Drug Application,Convene an advisory committee meeting on MDMA-Assisted Therapy with an extended Open Public Hearing prioritizing concerns about Lykos Therapeutics' application,"Petitioner argues that the MDMA-assisted therapy application is novel and precedent-setting, involves significant safety concerns, unresolved scientific issues, and high public interest. The petitioner also raises ethical and regulatory concerns over data reporting, protocol safety, and internal culture at Lykos/MAPS, calling for independent expert input and transparency."
FDA-2024-P-2150-0001_Envelope.pdf,04/25/2024,,"Parenteral Technologies, LLC","Michael A. Creaturo, submitting on behalf of Parenteral Technologies, LLC",Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned
FDA-2024-P-2151-0001_Citizen_Petition_from_UnidosUS.pdf,"May 7, 2024",,UnidosUS,"No, UnidosUS is not representing another entity but has co-signatories from other organizations","5 U.S.C. § 553(e), 21 C.F.R. § 10.30, Section 403(a) of the Food, Drug, and Cosmetic Act",Voluntary fortification policy and labeling practices for unfortified corn masa flour and products,Require a warning label on all unfortified corn masa flour and products made with corn masa to inform consumers of the lack of folic acid and associated risk of neural tube defects,"Voluntary fortification has failed to ensure adequate folic acid intake among Hispanic women, resulting in persistent health disparities; a warning label is needed to alert consumers and drive public health improvement"
FDA-2024-P-2215-0001_Citizen_Petition_from_Metaltronica_Spa.pdf,"May 2, 2024",,Metaltronica Spa,"No, the submitting entity is not representing another entity","21 CFR §10.25(a), 21 CFR §10.30, IEC 60601-1, IEC 60601-2, IEC 60601-2-28, IEC 60601-1-3, IEC 60601-2-45, IEC 62304, ISO 14971",FDA classification and premarket submission requirements for tomo digital mammography devices (product code OTE),"Reclassify tomo digital mammography devices (product code OTE) from Class III (PMA) to Class II (510(k)), aligning them with Full Field Digital Mammography (FFDM) devices (product code MUE)","The petitioner argues that risks and necessary evidence for OTE devices are similar to those for MUE devices, both of which use ionizing radiation and share hardware/software components. The technology is mature, widely adopted globally, and supported by harmonized standards. Market data and adverse event analysis show no significant safety differences, and reclassification would reduce costs for manufacturers, regulators, and users while maintaining safety and effectiveness."
FDA-2024-P-2220-0001_Citizen_Petition_from_Encube_Ethicals_Private_Limi.pdf,"May 6, 2024",,Encube Ethicals Private Limited,"No, the submitting entity is not representing another entity","21 C.F.R. § 10.25(a), 21 C.F.R. § 10.30, 21 C.F.R. § 314.161, 21 C.F.R. § 314.122, 21 C.F.R. § 25.31(a)",Determination of whether the Reference Listed Drug (RLD) PENNSAID (diclofenac sodium topical solution 2%) has been withdrawn for reasons of safety or effectiveness,"Determine whether PENNSAID (diclofenac sodium topical solution 2% w/w, NDA# N204623) has been withdrawn for reasons of safety or effectiveness",The petitioner believes the discontinuation was for commercial reasons and not related to safety or effectiveness. A determination from the FDA is required to allow referencing the RLD in an ANDA.
FDA-2024-P-2242-0001_Citizen_Petition_from_David_Behar_Redacted.pdf,"April 28, 2024",,"David Behar, M.D.","No, the submitting entity is not representing another entity","21 C.F.R. § 10.30, 21 C.F.R. § 10.40(e)(1), Administrative Procedure Act",FDA requirement for a prescription to obtain CPAP machines,"Make CPAP (Continuous Positive Airway Pressure) machines available over the counter without a prescription, and require sellers to provide instruction manuals at a 6th-grade reading level with illustrations","The petitioner argues that requiring prescriptions for CPAP machines results in high costs, delays, and limited access, contributing to untreated sleep apnea, increased healthcare costs, preventable accidents, and health disparities. The petitioner cites successful price drops following over-the-counter access to hearing aids, points to racial and economic inequities, and contends that self-diagnosis is feasible with support from sleep apps and partner observations. The petition invokes urgent public health and economic consequences to justify bypassing traditional rulemaking procedures."
FDA-2024-P-2272-0001_Citizen_Petition_from_Aurobindo_Pharma_USA__Inc_.pdf,"May 7, 2024",,Aurobindo Pharma Limited,"Blessy Johns, US Agent for Aurobindo Pharma Limited (Aurobindo Pharma USA, Inc.)","Section 505(j) of the FDCA, 21 CFR § 10.25(a), 21 CFR § 10.30, 21 CFR § 314.122, 21 CFR § 314.161, 21 CFR § 25.31(a), 21 CFR § 25.15(d), 21 CFR § 10.30(b)","Determination regarding whether INVEGA® (Paliperidone) Extended-Release Tablets 1.5 mg, NDA #021999, has been withdrawn for safety or effectiveness reasons",Request the FDA to determine whether INVEGA® (Paliperidone) Extended-Release Tablets 1.5 mg has been withdrawn for reasons of safety or effectiveness,The petitioner notes that the drug appears in the discontinued section of the Orange Book and seeks confirmation that the discontinuation was not due to safety or effectiveness concerns in order to support an Abbreviated New Drug Application (ANDA)
FDA-2024-P-2314-0001_Citizen_Petition_from_Aurobindo_Pharma_USA_Inc_.pdf,"May 9, 2024",,Aurobindo Pharma Limited,"Blessy Johns, US Agent for Aurobindo Pharma Limited (Aurobindo Pharma USA, Inc.)","Section 505(j) of the FDCA, 21 CFR § 10.25(a), 21 CFR § 10.30, 21 CFR § 314.122, 21 CFR § 314.161, 21 CFR § 314.162, 21 CFR § 25.31(a), 21 CFR § 25.15(d), 21 CFR § 10.30(b)","Determination regarding whether Augmentin XR (amoxicillin and clavulanate potassium) extended-release tablets, NDA 050785, has been withdrawn for reasons of safety or effectiveness","Request the FDA to determine whether Augmentin XR (amoxicillin and clavulanate potassium) extended-release tablets, NDA 050785, has been voluntarily withdrawn from sale for reasons of safety or effectiveness","The petitioner notes that Augmentin XR now appears in the discontinued section of the Orange Book and requests confirmation that the withdrawal was not due to safety or effectiveness concerns, in order to support an Abbreviated New Drug Application (ANDA)"
FDA-2024-P-2326-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,"May 10, 2024",,"Hyman, Phelps & McNamara, P.C.",United Therapeutics Corporation,"21 C.F.R. §§ 10.30 and 10.31, 21 U.S.C. §§ 355(b)(1)(A)(iv), 355(d)(3), 355(e), 351(a)(2)(B); 21 C.F.R. §§ 314.50(d), 314.105(a), 314.107(b)(4), 314.110(a), 314.125(a)(3)-(b)(1), (b)(4), (b)(13); 21 C.F.R. § 25.31(a)",FDA’s tentative approval of Liquidia’s section 505(b)(2) NDA for YUTREPIA,"Rescind tentative approval of Liquidia's NDA for YUTREPIA, issue a Complete Response Letter, and withhold any final approval until compliance with CGMP is ensured","The sole API supplier for YUTREPIA, LGM Pharma, has a history of severe and ongoing CGMP violations, and remains under a Consent Decree. These violations threaten the safety, quality, and compliance of YUTREPIA’s supply chain, and thus the product should not be approved or tentatively approved until all issues are remediated and FDA confirms compliance."
FDA-2024-P-2379-0001_Citizen_Petition_from_The_Humane_Society_of_the_Un.pdf,"May 15, 2024",,The Humane Society of the United States and the Humane Society Legislative Fund,Not representing another entity; the petition is submitted on behalf of HSUS and HSLF themselves,"21 U.S.C. § 301 et seq., 5 U.S.C. § 553(e), 21 C.F.R. § 10.30",FDA's regulatory policies and guidance that imply animal testing is required for drug approval,"Amend FDA regulations and guidance to clarify that animal testing is not required, issue a new guidance document detailing accepted non-animal methods (NAMs), and update all future guidance documents to reference the new NAMs guidance","Animal testing is often unnecessary, expensive, time-consuming, and not required by law. Non-animal methods (NAMs) are more efficient, reliable, and ethical. Current FDA language creates confusion and incentivizes unnecessary animal tests, hindering drug innovation and violating Congressional intent under FDORA"
FDA-2024-P-2461-0001_Citizen_Petition_from_Ho_Chunk__Inc__on_behalf_of_.pdf,"May 17, 2024",,"Ho-Chunk, Inc.","Yes, Ho-Chunk, Inc. is submitting on behalf of Rock River Manufacturing Company","21 U.S.C. § 301 et seq., 21 C.F.R. § 10.30, Executive Order 13175, HHS Tribal Consultation Policy","Requirements for Tobacco Product Manufacturing Practice (FDA-2013-N-0227), specifically part 1120",Amend the Proposed Rule to include an exemption from part 1120 for tribally-owned cigarette manufacturers such as Rock River Manufacturing,"The petitioner argues that the proposed rule imposes significant economic burdens on small tribal manufacturers like Rock River, threatening their viability. Rock River is one of only two tribally-owned tobacco manufacturers in the U.S., and it already operates under strict tribal regulation and high compliance standards. An exemption would allow the tribe to preserve jobs and economic activity on the Winnebago Reservation without materially affecting overall tobacco regulation."
FDA-2024-P-2482-0001_Citizen_Petition_from_Age_Reversal_Unity.pdf,"May 7, 2024",,Age Reversal Unity,"No, the submitting entity is not representing another entity","21 C.F.R. § 10.30, 21 C.F.R. § 25.32",Lack of regulation classifying aging as a disease,"Request the FDA to promulgate a new regulation classifying aging as a disease for purposes of research, treatment, and prevention","Aging is the primary risk factor for many chronic diseases and has identifiable biological hallmarks that are targetable. Recognizing aging as a disease could shift the healthcare paradigm to proactive aging management, increase research funding, and streamline regulatory pathways for relevant therapies."
FDA-2024-P-2513-0001_Citizen_Petition_from_Innogenix_LLC.pdf,"May 21, 2024",,Innogenix LLC,"No, the submitting entity is not representing another entity","21 C.F.R. §§ 10.25, 10.30, 314.122, 314.161; Sections 505(j) and 505(w) of the Federal Food, Drug, and Cosmetic Act","Determination of whether the Reference Listed Drug (RLD), Flagyl® (metronidazole) Tablets 250 mg and 500 mg (NDA N012623), has been withdrawn for safety or effectiveness reasons","Request that the FDA determine whether Flagyl® Tablets 250 mg and 500 mg, approved under NDA N012623, has been voluntarily withdrawn for safety or effectiveness reasons",The petitioner believes the discontinuation was due to commercial reasons and is not aware of any safety or effectiveness concerns. A determination by FDA is required to enable ANDA submissions referencing the RLD.
FDA-2024-P-2514-0001_Citizen_Petition_from_Zydus_Pharmaceuticals__USA__.pdf,"May 22, 2024",,Zydus Pharmaceuticals (USA) Inc.,"No, the submitting entity is not representing another entity","21 C.F.R. § 10.25(a), 21 C.F.R. § 10.30, 21 C.F.R. § 314.161, 21 C.F.R. § 314.122, 21 C.F.R. § 25.31(a), 21 C.F.R. § 10.30(b)","Determination of whether the Reference Listed Drug (RLD) NUPLAZID® (pimavanserin) tablets, 17 mg (NDA# N207318) has been withdrawn for reasons of safety or effectiveness","Request that the FDA determine whether NUPLAZID® (pimavanserin) tablets, 17 mg (NDA# N207318) has been withdrawn from commercial sale for reasons of safety or effectiveness",The petitioner states that NUPLAZID® 17 mg appears in the Discontinued Section of the Orange Book but is unaware of any safety or effectiveness issues. They believe the discontinuation was for commercial reasons and seek FDA’s confirmation to support an ANDA referencing the drug
FDA-2024-P-2515-0001_Citizen_Petition_from_Encube_Ethicals_Private_Limi.pdf,"May 22, 2024",,Encube Ethicals Private Limited,"No, the submitting entity is not representing another entity","21 C.F.R. § 10.25(a), 21 C.F.R. § 10.30, 21 C.F.R. § 314.161, 21 C.F.R. § 314.122, 21 C.F.R. § 25.31(a), 21 C.F.R. § 10.30(b)","Determination of whether the Reference Listed Drug (RLD), Fortesta (testosterone) Gel (10 mg/0.5 gm Actuation, NDA# 021463), has been withdrawn for reasons of safety or effectiveness","Request the FDA to determine whether Fortesta (testosterone) Gel (10 mg/0.5 gm Actuation, NDA# 021463) has been voluntarily withdrawn from commercial sale for safety or effectiveness reasons","The petitioner states that Fortesta appears in the Discontinued Section of the Orange Book but is unaware of any safety or effectiveness concerns. Believing the withdrawal was due to commercial reasons, the petitioner seeks FDA confirmation to enable an ANDA referencing the drug"
FDA-2024-P-2538-0001_Suitability_Petition_from_Hyman__Phelps___McNamara.pdf,"May 23, 2024",,"Hyman, Phelps & McNamara, P.C.","Yes, the law firm is submitting the petition on behalf of a client (not named)","Section 505(j)(2)(C) of the FDC Act, 21 C.F.R. § 314.93, 21 C.F.R. §§ 10.20 and 10.30, 21 C.F.R. § 25.31, 21 C.F.R. § 10.30(b), FDC Act § 505B(a)(1)(A)(i)",Suitability of a new dosage form for Cetrorelix Acetate (pre-filled syringe solution) as an ANDA based on RLD CETROTIDE® (powder for reconstitution),Request that FDA declare Cetrorelix Acetate Injection 0.25 mg/mL pre-filled syringe suitable for submission as an ANDA,"The proposed product is a ready-to-use form with the same active ingredient, strength, route of administration, and indications as the RLD, reducing the risk of medication error and improving ease of use. The change in dosage form does not affect safety or efficacy, and the product is not intended for pediatric patients, supporting a PREA waiver."
FDA-2024-P-2730-0001_Citizen_Petition_from_Kenneth_D__Eichenbaum.pdf,"June 2, 2024",,"Kenneth D. Eichenbaum, MD, MSE","No, the submitting entity is not representing another entity","21 C.F.R. § 10.20, 21 C.F.R. § 10.30, Section 351 of the Public Health Service Act, 21 C.F.R. § 25.30, 21 C.F.R. § 25.31, 21 C.F.R. § 10.30(b)","FDA’s potential action to expand the label for SRP-9001 (Elvidys, delandistrogene moxeparvovec-rokl)",Request that the FDA refrain from authorizing an expanded label for SRP-9001 (Elvidys) and re-evaluate its limited benefit relative to associated risks,"The petition argues that both Phase 2 and Phase 3 trials failed to meet their primary endpoints, with weak evidence of benefit and significant safety risks including liver injury, myocarditis, and immune-mediated myositis. Expanding the label may hinder the development of more promising therapies, waste resources, and damage FDA's credibility. Additional studies and alternative therapies should be prioritized."
FDA-2024-P-2752-0001_Suitability_Petition_from_Hyman__Phelps___McNamara.pdf,"June 6, 2024",,"Hyman, Phelps & McNamara, P.C.","Yes, the submitting entity is representing an unnamed client","Section 505(j)(2)(C) of the FDC Act, 21 C.F.R. § 314.93, 21 C.F.R. §§ 10.20 and 10.30, 21 C.F.R. § 25.31, 21 C.F.R. § 10.30(b)","Suitability determination for Bupivacaine Hydrochloride Injection, USP (pharmacy bulk package) as an ANDA referencing MARCAINE (NDA 016964)","Request that FDA declare Bupivacaine Hydrochloride Injection, USP in pharmacy bulk packages (100 mL, 500 mL, 1L, 2L) of 0.25% and 0.5% strengths suitable for submission as an ANDA","The petitioner asserts that the proposed bulk packaging has the same concentration and dosage form as the RLD but offers operational advantages such as reduced waste and increased supply to mitigate drug shortages. The labeling includes necessary safety instructions and does not raise new questions of safety or efficacy, so no clinical investigations are required. The PREA requirements do not apply."
FDA-2024-P-2753-0001_Suitability_Petition_from_Hyman__Phelps___McNamara.pdf,"June 6, 2024",,"Hyman, Phelps & McNamara, P.C.","Yes, the submitting entity is representing an unnamed client","Section 505(j)(2)(C) of the FDC Act, 21 C.F.R. § 314.93, 21 C.F.R. §§ 10.20 and 10.30, 21 C.F.R. § 25.31, 21 C.F.R. § 10.30(b), FDC Act § 505B(a)(1)(A)(i)","Suitability determination for submission of an ANDA for a new presentation of Fentanyl Citrate Injection, USP","Request that FDA declare Fentanyl Citrate Injection, USP, 50 mcg/mL in pharmacy bulk packages (100 mL, 500 mL, 1L, and 2L) suitable for submission as an ANDA","The petitioner argues that while the proposed drug differs from the RLD only in total fill volume/total drug content, the concentration and therapeutic use remain the same. Bulk packaging will reduce waste, support operational efficiencies, and help mitigate ongoing drug shortages. PREA requirements do not apply, and no clinical investigations are necessary to demonstrate safety or efficacy."
FDA-2024-P-2757-0001_Suitability_Petition_from_Hyman__Phelps___McNamara.pdf,"June 6, 2024",,"Hyman, Phelps & McNamara, P.C.","Yes, the submitting entity is representing an unnamed client","Section 505(j)(2)(C) of the FDC Act, 21 C.F.R. § 314.93, 21 C.F.R. §§ 10.20 and 10.30, 21 C.F.R. § 25.31, 21 C.F.R. § 10.30(b), FDC Act § 505B(a)(1)(A)(i)","Suitability determination for Oxytocin Injection, USP (synthetic), 10 USP Units/mL, for submission as an ANDA in pharmacy bulk package sizes","Request that FDA declare Oxytocin Injection, USP (synthetic), 10 USP Units/mL, in pharmacy bulk packages (100 mL, 500 mL, 1L, and 2L) suitable for submission as an ANDA","The proposed product has the same concentration and intended therapeutic use as the RLD, but differs in total fill volume/total drug content. The larger volume pharmacy bulk packaging aims to reduce waste, improve operational efficiency, and help prevent potential drug shortages. No new safety or efficacy issues are raised. PREA does not apply, and FDA has approved similar petitions in the past."
FDA-2024-P-2758-0001_Suitability_Petition_from_Hyman__Phelps___McNamara.pdf,"June 6, 2024 :contentReference[oaicite:0]{index=0}:contentReference[oaicite:1]{index=1}",,"Hyman, Phelps & McNamara, P.C. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}",Petition submitted by the law firm on behalf of an unnamed client (entity not disclosed) :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5},"Section 505(j)(2)(C) FDC Act; 21 C.F.R. § 314.93; 21 C.F.R. §§ 10.20, 10.30; Section 505(j)(2)(A)(iii) FDC Act; 21 C.F.R. § 314.3; Section 505B(a)(1)(A)(i) FDC Act (PREA); 21 C.F.R. § 25.31; 21 C.F.R. § 10.30(b) :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7}",FDA’s determination of suitability for an ANDA for Ropivacaine Hydrochloride Injection in pharmacy bulk package sizes :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},"Declare that pharmacy bulk packages (100 mL, 500 mL, 1 L, 2 L) of Ropivacaine Hydrochloride Injection (0.2 %, 0.5 %, 1 %) are suitable for submission as an ANDA :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11}","Change is limited to total fill volume/drug content while concentration, dosage, route, and labeling remain consistent with the RLD; larger bulk packages reduce waste, improve operational efficiency, lower costs, and help mitigate an ongoing drug shortage; prior FDA precedents for similar petitions; no new safety or efficacy questions; PREA not applicable; categorical environmental exclusion claimed :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}"
FDA-2024-P-2778-0001_Suitability_Petition_from_Pharmobedient_Consulting.pdf,"June 7, 2024 :contentReference[oaicite:0]{index=0}:contentReference[oaicite:1]{index=1}",,"Pharmobedient Consulting, LLC :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}","Pharmobedient Consulting, LLC submitting on behalf of Pharmobedient Pharmaceuticals, LLC (product sponsor) :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5}",Section 505(j)(2)(C) FDC Act; Section 505(j)(2)(C)(iii) FDC Act; 21 C.F.R. § 10.20; 21 C.F.R. § 10.30; 21 C.F.R. § 314.93; 21 C.F.R. § 25.31; Pediatric Research Equity Act (PREA) Section 505B :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},FDA’s determination of suitability for an ANDA for Chlorzoxazone Orally Disintegrating Tablets (ODT) 250 mg and 500 mg differing in dosage form from the RLD :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},Declare that Chlorzoxazone ODT 250 mg and 500 mg are suitable for submission in an ANDA under Section 505(j)(2)(C) :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11},"ODT provides rapid onset without water, improves compliance for patients with swallowing difficulties, offers dosage flexibility with added 250 mg strength, aligns with existing labeling and bioequivalence to RS, raises no new safety or efficacy questions, environmental exclusion claimed, and pediatric studies waiver requested under PREA :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}"
FDA-2024-P-2779-0001_Suitability_Petition_from_Hyman__Phelps___McNamara.pdf,"June 10, 2024 :contentReference[oaicite:0]{index=0}:contentReference[oaicite:1]{index=1}",,"Hyman, Phelps & McNamara, P.C. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}",Law firm filing on behalf of an unnamed client :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5},"Section 505(j)(2)(C) FDC Act; Section 505(j)(2)(A)(iii) FDC Act; Section 505B(a)(1)(A)(i) FDC Act (PREA); 21 C.F.R. § 314.93; 21 C.F.R. §§ 10.20, 10.30; 21 C.F.R. § 10.33; 21 C.F.R. § 25.31 :contentReference[oaicite:6]{index=6}",FDA’s prior denial and determination of suitability for an ANDA for Diclofenac Potassium Tablets 12.5 mg differing in strength from the RLD CATAFLAM :contentReference[oaicite:7]{index=7}:contentReference[oaicite:8]{index=8},Declare Diclofenac Potassium Tablets 12.5 mg suitable for submission as an ANDA under Section 505(j) :contentReference[oaicite:9]{index=9}:contentReference[oaicite:10]{index=10},"Proposed lower strength supports lowest effective dosing, literature and bioavailability studies show comparable safety and efficacy to higher strengths, EMA precedent confirms acceptability, no new safety or labeling concerns, PREA inapplicable, and categorical environmental exclusion claimed :contentReference[oaicite:11]{index=11}"
FDA-2024-P-2843-0001_Citizen_Petition_from_Zach_Richardson_Redacted.pdf,"June 8, 2024 :contentReference[oaicite:0]{index=0}:contentReference[oaicite:1]{index=1}",,Zach Richardson :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3},Petition filed by Zach Richardson on his own behalf; no separate represented entity :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5},"21 C.F.R. § 10.30; 21 C.F.R. § 10.30(b); 21 C.F.R. § 25.30; 21 C.F.R. § 25.31; Federal Food, Drug, and Cosmetic Act :contentReference[oaicite:6]{index=6}",FDA’s current policy of not classifying aging as a disease; petitioner seeks issuance of a new regulation to change this :contentReference[oaicite:7]{index=7}:contentReference[oaicite:8]{index=8},Issue a regulation classifying aging as a disease :contentReference[oaicite:9]{index=9}:contentReference[oaicite:10]{index=10},"Aging drives most chronic diseases and economic burden; scientific evidence links biomarkers and pathways with potential interventions; recognizing aging as a disease would spur R&D, improve healthspan, and reduce healthcare costs, with precedents such as obesity classification noted alongside acknowledgment of possible Social Security impacts :contentReference[oaicite:11]{index=11}"
FDA-2024-P-2846-0001_Petition_for_Reclassification_from_Pyrexar_Medical.pdf,"June 6, 2024 :contentReference[oaicite:1]{index=1}",,Pyrexar Medical Inc. :contentReference[oaicite:3]{index=3},Petition filed directly by Pyrexar Medical Inc.; no separate representative entity :contentReference[oaicite:5]{index=5},"Section 513(e) of the Federal Food, Drug, and Cosmetic Act :contentReference[oaicite:7]{index=7}",FDA’s classification of the BSD‑2000 Hyperthermia System as a Class III medical device :contentReference[oaicite:9]{index=9},Reclassify the BSD‑2000 Hyperthermia System from Class III to Class II under Section 513(e) :contentReference[oaicite:11]{index=11},"Extensive clinical data show the BSD‑2000’s proven safety and efficacy; years of global clinical use confirm low risk; advanced safety features and precise temperature control align with Class II expectations; reclassification would streamline access, cut regulatory costs, broaden adoption, and improve patient outcomes while matching precedents for similar devices "
FDA-2024-P-2885-0001_Suitability_Petition_from_Hyman__Phelps___McNamara.pdf,"June 17, 2024 :contentReference[oaicite:0]{index=0}:contentReference[oaicite:1]{index=1}",,"Hyman, Phelps & McNamara, P.C. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}",Law firm submitting on behalf of an unnamed client :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5},"Section 505(j)(2)(C) FDC Act; Section 505(j)(2)(A)(iii) FDC Act; Section 505B(a)(1)(A)(i) FDC Act (PREA); 21 C.F.R. § 314.93; 21 C.F.R. §§ 10.20, 10.30; 21 C.F.R. § 25.31 :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7}",FDA’s determination of suitability for an ANDA for new 200 mg and 300 mg strengths of Olaparib Tablets differing from the RLD strengths :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},Declare Olaparib Tablets 200 mg and 300 mg suitable for submission as an ANDA under Section 505(j) :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11},"Strengths align with RLD dosing recommendations, reduce tablet burden, raise no new safety or efficacy questions, PREA inapplicable to strength changes, and categorical environmental exclusion claimed :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}"
FDA-2024-P-2909-0001_Suitability_Petition_from_Hyman__Phelps___McNamara.pdf,"June 17, 2024 :contentReference[oaicite:0]{index=0}:contentReference[oaicite:1]{index=1}",,"Hyman, Phelps & McNamara, P.C. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}",Law firm filing on behalf of an unnamed client :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5},"Section 505(j)(2)(C) FDC Act; Section 505(j)(2)(A)(iii) FDC Act; 21 C.F.R. § 314.93; 21 C.F.R. §§ 10.20, 10.30; Section 505B(a)(1)(A)(i) FDC Act (PREA); 21 C.F.R. § 25.31 :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7}",FDA’s determination of suitability for an ANDA for new 4 mg and 12 mg Buprenorphine Sublingual Tablet strengths differing from the RLD SUBUTEX :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},Declare Buprenorphine Sublingual Tablets 4 mg and 12 mg suitable for submission as an ANDA under Section 505(j) :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11},"Strengths match RLD dosing guidance, reduce pill burden, introduce no new safety or efficacy concerns, PREA requirements do not apply to strength changes, and a categorical environmental exclusion is claimed :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}"
FDA-2024-P-2932-0001_Suitability_Petition_from_Newcastle_Bioscience_LLC.pdf,"June 19, 2024 :contentReference[oaicite:0]{index=0}:contentReference[oaicite:1]{index=1}",,Newcastle Bioscience LLC :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3},Newcastle Bioscience LLC submitting on behalf of an unnamed client :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5},Section 505(j)(2)(C) FDC Act; 21 C.F.R. § 10.30; 21 C.F.R. § 314.93; 21 C.F.R. § 25.31; Pediatric Research Equity Act (PREA) Section 505B; Section 505B(k) FDC Act :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},"FDA’s determination of suitability for an ANDA for Rosuvastatin Calcium Orally Disintegrating Tablets (5 mg, 10 mg, 20 mg, 40 mg) differing in dosage form from the RLD Crestor Tablets :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9}","Declare Rosuvastatin Calcium Orally Disintegrating Tablets 5 mg, 10 mg, 20 mg, 40 mg suitable for submission as an ANDA under Section 505(j) :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11}","Change limited to dosage form while strengths, dosing schedule, and labeling match RLD; ODT improves patient convenience without new safety or efficacy issues; no clinical concerns raised; pediatric study waiver requested; categorical environmental exclusion claimed :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}"
FDA-2024-P-2933-0001_Citizen_Petition_from_Chobani_LLC.pdf,"June 18, 2024 :contentReference[oaicite:0]{index=0}:contentReference[oaicite:1]{index=1}",,"Chobani, LLC :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}","Petition filed directly by Chobani, LLC; no separate represented entity :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5}",Section 401 FDC Act; 21 C.F.R. § 131.200; 21 C.F.R. § 131.200(b); 21 C.F.R. § 101.4(b)–(c); 21 C.F.R. § 25.30; 21 C.F.R. § 25.31; 21 C.F.R. § 25.32(a) :contentReference[oaicite:6]{index=6},"FDA’s yogurt standard of identity at 21 C.F.R. § 131.200, which currently excludes ultrafiltered nonfat milk as a basic dairy ingredient :contentReference[oaicite:7]{index=7}:contentReference[oaicite:8]{index=8}",Initiate rulemaking to amend 21 C.F.R. § 131.200 to include ultrafiltered nonfat milk as a basic dairy ingredient in yogurt :contentReference[oaicite:9]{index=9}:contentReference[oaicite:10]{index=10},"Ultrafiltered nonfat milk maintains yogurt’s essential qualities, enables modern processing, offers higher protein with lower sugar/lactose, supports consumer demand for lactose‑free/high‑protein foods, harmonizes with FDA nutrition goals and international standards, and raises no new safety, environmental, or economic concerns :contentReference[oaicite:11]{index=11}"
FDA-2024-P-2952-0001_Citizen_Petition_from_Sarah_A__Norring___Redacted.pdf,"June 20, 2024 :contentReference[oaicite:0]{index=0}:contentReference[oaicite:1]{index=1}",,"Sarah A. Norring, Ph.D. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}",Petition filed by Sarah A. Norring on her own behalf; no represented entity :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5},21 C.F.R. § 10.30; 21 C.F.R. § 314.161; 21 C.F.R. § 25.31 :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},FDA’s determination under 21 C.F.R. § 314.161 regarding whether the listed drug Lunelle was withdrawn for safety or effectiveness reasons :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},Conclude that Lunelle (estradiol cypionate/medroxyprogesterone acetate injectable) was not withdrawn from sale for safety or effectiveness reasons :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11},"Historical evidence shows only syringe recall due to potency uncertainty; vials retained full efficacy, no safety concerns cited; subsequent market withdrawal driven by manufacturing/business decisions rather than safety or effectiveness; therefore, FDA should find the withdrawal not safety‑related :contentReference[oaicite:12]{index=12}"
FDA-2024-P-2955-0001_Citizen_Petition_from_Dsquare_LLC.pdf,"June 18, 2024 :contentReference[oaicite:0]{index=0}:contentReference[oaicite:1]{index=1}",,Dsquare LLC :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3},Petition filed directly by Dsquare LLC; no separate represented entity :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5},21 C.F.R. § 10.30; 21 C.F.R. § 201; 21 C.F.R. § 201.64; 21 C.F.R. § 201.57 :contentReference[oaicite:6]{index=6},"Current FDA labeling policy for sodium‑containing N‑acetylcysteine drugs used in treating acetaminophen intoxication, which lacks required sodium warnings and black‑box alerts :contentReference[oaicite:7]{index=7}:contentReference[oaicite:8]{index=8}",Amend labeling of all sodium‑containing N‑acetylcysteine products to add a high‑sodium content warning for the general population and a Black Box Warning for salt‑sensitive patients or those with cardiovascular/CNS disease :contentReference[oaicite:9]{index=9},"Recommended treatment delivers sodium doses far exceeding FDA limits; high acute sodium loads are linked to serious cardiovascular and neurological events and reported fatalities; existing FDA guidelines and the former RLD CETYLEV include such warnings, but current products do not; adding warnings will protect salt‑sensitive and general populations and align labeling with FDA safety standards :contentReference[oaicite:10]{index=10}"
FDA-2024-P-3090-0001_Suitability_Petition_from_Epic_Pharma__LLC__on_beh.pdf,"June 28, 2024 :contentReference[oaicite:0]{index=0}:contentReference[oaicite:1]{index=1}",,"Epic Pharma, LLC :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}","Epic Pharma, LLC filed the petition as Regulatory Agent on behalf of Humanwell Pharmaceutical US, Inc. :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5}",Section 505(j)(2)(C) FD&C Act; 21 C.F.R. § 314.93; 21 C.F.R. § 10.20; 21 C.F.R. § 10.30; 21 C.F.R. § 25.31; Pediatric Research Equity Act (§ 505B) :contentReference[oaicite:6]{index=6},FDA’s determination of suitability for an ANDA differing in dosage form/strength from the RLD APTIOM—specifically Eslicarbazepine Acetate Oral Suspension 50 mg/mL :contentReference[oaicite:7]{index=7}:contentReference[oaicite:8]{index=8},Declare Eslicarbazepine Acetate Oral Suspension 50 mg/mL suitable for submission as an ANDA under § 505(j) :contentReference[oaicite:9]{index=9}:contentReference[oaicite:10]{index=10},"Change is limited to converting APTIOM tablets to a ready‑to‑use suspension at an equivalent dosage; labeling, dosing schedule, and safety/efficacy remain unchanged; suspension aids patients who cannot swallow tablets; precedent for approving similar dosage‑form petitions; no new clinical concerns; petitioner seeks PREA waiver and claims categorical environmental exclusion :contentReference[oaicite:11]{index=11}"
FDA-2024-P-3188-0001_Suitability_Petition_from_Lachman_Consulting_Servi.pdf,"July 3, 2024 :contentReference[oaicite:0]{index=0}:contentReference[oaicite:1]{index=1}",,"Lachman Consulting Services, Inc. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}","Lachman Consulting Services, Inc. filed the petition on behalf of an unnamed client :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5}",Section 505(j)(2)(C) FD&C Act; Section 505B FD&C Act (PREA); 21 C.F.R. § 10.20; 21 C.F.R. § 10.30; 21 C.F.R. § 25.31 :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},"FDA’s determination of suitability for an ANDA for a new 1,250 mg/100 mL (12.5 mg/mL) strength of Levetiracetam in Sodium Chloride Injection differing from RLD strengths :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9}","Declare Levetiracetam in Sodium Chloride Injection 1,250 mg/100 mL (12.5 mg/mL) suitable for submission as an ANDA under Section 505(j) :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11}","Proposed strength is bracketed by existing RLD strengths, reduces medical waste, avoids multiple infusions or compounding, maintains same active ingredient, route, indications, and labeling, introduces no new safety or efficacy concerns, PREA deemed inapplicable, and categorical environmental exclusion claimed :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}"
FDA-2024-P-3292-0001_Suitability_Petition_from_Felix_Pharmaceuticals_Pv.pdf,"July 10, 2024 :contentReference[oaicite:0]{index=0}:contentReference[oaicite:1]{index=1}",,Felix Pharmaceuticals Pvt. Ltd. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3},Petition filed directly by Felix Pharmaceuticals Pvt. Ltd.; no represented third party :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5},Section 512(n)(3) FD&C Act; 21 C.F.R. § 25.30(h); 21 C.F.R. § 25.21 :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},FDA’s determination of suitability for an abbreviated new animal drug application (ANADA) for a Maropitant Citrate oral solution differing in dosage form from the pioneer CERENIA tablets :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},Declare that Maropitant Citrate Oral Solution 40 mg/mL is suitable for submission as an ANADA under Section 512(n)(3) :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11},"Only dosage‑form change—from tablet to oral solution—with same active ingredient, route, and dosage; proposed solution will be bioequivalent, uses excipients already approved for dogs, allows precise weight‑based dosing via calibrated syringes, improves ease of administration, and poses no new safety or efficacy concerns; categorical environmental exclusion claimed :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}"
FDA-2024-P-3293-0001_Suitability_Petition_from_Newcastle_Bioscience_LLC.pdf,"July 9, 2024 :contentReference[oaicite:0]{index=0}:contentReference[oaicite:1]{index=1}",,Newcastle Bioscience LLC :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3},Petition filed directly by Newcastle Bioscience LLC; no separate represented entity :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5},Section 505(j)(2)(C) FDC Act; 21 C.F.R. § 10.30; 21 C.F.R. § 25.31; Pediatric Research Equity Act (§ 505B) :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},FDA’s determination of suitability for an ANDA for Lacosamide Orally Disintegrating Tablets that differ in dosage form and strengths from the RLD Vimpat tablets :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},"Declare Lacosamide Orally Disintegrating Tablets 25 mg, 37.5 mg, 75 mg, 112.5 mg, 125 mg, and 175 mg suitable for submission as an ANDA under Section 505(j) :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11}","New strengths and ODT form provide flexible dosing (especially for renal/hepatic impairment and pediatrics), facilitate titration to lowest effective dose, remove need for oral solution, offer ease of administration, introduce no new safety or efficacy concerns, seek PREA waiver, and claim categorical environmental exclusion :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}"
FDA-2024-P-3357-0001_Citizen_Petition_from_Randall_Steinmeyer___Redacte.pdf,Not stated in the petition,,Randall Steinmeyer,None—petitioner appears on his own behalf,"Federal Food, Drug & Cosmetic Act; 21 C.F.R. Part 809 (Medical Devices; Laboratory Developed Tests)",FDA’s delegation of oversight for DNA paternity‑test LDTs to the American Association of Blood Banks (AABB) instead of direct regulation,"Ban LabCorp and DDC’s forged DNA paternity tests, place such tests under direct FDA regulation, remove AABB as regulator, and bar the respondents from marketing LDTs","Tests are alleged forgeries mislabeled as paternity tests; respondents control the market, switched real tests for cheap forgeries, forged expert signatures, lied to FDA about forensic validity, and profit from fraud—creating public‑health and justice risks that require immediate FDA action"
FDA-2024-P-3479-0001_Citizen_Petition_from_Jingwei_Pharmaceutical_Compa.pdf,"July 23, 2024 :contentReference[oaicite:0]{index=0}:contentReference[oaicite:1]{index=1}",,"Jingwei Pharmaceutical Company, Ltd. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}","Petition submitted directly by Jingwei Pharmaceutical Company, Ltd.; no separate represented entity :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5}",21 U.S.C. § 355; 21 C.F.R. § 10.25; 21 C.F.R. § 10.30; 21 C.F.R. § 25.30; 21 C.F.R. § 25.31 :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},FDA’s oversight and approval standards for generic drug manufacturers that use a biocatalytic process to produce sitagliptin active pharmaceutical ingredient (API) :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},"Require such manufacturers to submit (1) a complete certificate of analysis for the biocatalyst, (2) detailed preparation process for the biocatalyst, (3) analytical protocols for residual enzymes and biological impurities, and (4) purging strategies documenting the fate of the biocatalyst :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11}","Biocatalytic processes introduce complex enzyme‑related impurities that are hard to detect and purge; inconsistent impurity profiles threaten patient safety, especially for the large diabetic population relying on sitagliptin; many generics lack necessary technology, so stricter information requirements are needed to protect public health :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}"
FDA-2024-P-3482-0001_Citizen_Petition_from_Qilu_Pharmaceutical__Hainan_.pdf,"July 24, 2024 :contentReference[oaicite:0]{index=0}:contentReference[oaicite:1]{index=1}",,"Qilu Pharmaceutical (Hainan) Co., Ltd. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}","Petition filed directly by Qilu Pharmaceutical (Hainan) Co., Ltd.; no separate represented entity :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5}",Sections 505(j) and 505(w) FDC Act; 21 C.F.R. § 10.25(a); 21 C.F.R. § 10.30; 21 C.F.R. § 314.122; 21 C.F.R. § 314.161; 21 C.F.R. § 25.31 :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},"FDA’s listing of JESDUVROQ (daprodustat) tablets 1 mg, 2 mg, 4 mg, 6 mg, 8 mg in the Orange Book’s Discontinued Drug Product List and the related withdrawal determination :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9}",Determine that JESDUVROQ (daprodustat) tablets 1 mg–8 mg were not withdrawn for reasons of safety or effectiveness :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11},Petitioner is unaware of any safety or efficacy issues; believes discontinuation was solely for commercial reasons; a ‘not‑withdrawn‑for‑safety/efficacy’ finding will allow ANDA applicants to cite the drug as the RLD :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}
FDA-2024-P-3484-0001_Petition_for_Reclassification_of_next_generation_s.pdf,"June 28, 2024 :contentReference[oaicite:0]{index=0}:contentReference[oaicite:1]{index=1}",,"Foundation Medicine, Inc. :contentReference[oaicite:2]{index=2}:contentReference[oaicite:3]{index=3}","Petition filed directly by Foundation Medicine, Inc.; no separate represented entity :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5}",Section 513(f)(3) FD&C Act; Section 513(f)(1) FD&C Act; 21 C.F.R. § 860.123; 21 C.F.R. § 860.134 :contentReference[oaicite:6]{index=6}:contentReference[oaicite:7]{index=7},FDA’s current classification of next‑generation sequencing oncology panel devices (product code PQP) as Class III medical devices and its announced intent to reclassify IVDs :contentReference[oaicite:8]{index=8}:contentReference[oaicite:9]{index=9},Reclassify all NGS oncology panel devices with one or more companion diagnostic indications (product code PQP) from Class III to Class II (high‑risk with special controls) :contentReference[oaicite:10]{index=10}:contentReference[oaicite:11]{index=11},"Extensive regulatory experience and published data show risks can be mitigated through rigorous special controls; reclassification would preserve safety and effectiveness while improving patient access, ensuring high‑quality genomic testing, and aligning regulation with FDA’s 2024 reclassification initiative for high‑risk IVDs :contentReference[oaicite:12]{index=12}:contentReference[oaicite:13]{index=13}"
FDA-2024-P-3563-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,"July 29, 2024",,"Hyman, Phelps & McNamara, P.C.","Aquestive Therapeutics, Inc.",21 C.F.R. §§ 10.30 and 10.31; section 505(q) of the FDCA,FDA policy not requiring food-effect studies for intranasal products even when the active moiety has a known food effect,Require food-effect studies for intranasal spray products where the active moiety has a known food effect when administered orally; investigate lack of efficacy for such products documented in FDA's Adverse Event Reporting System,"Intranasal products may be partially swallowed and thus subject to food effects that alter pharmacokinetics and efficacy; literature and FAERS data suggest lack of efficacy could be due to unstudied food effects; a food-effect study is simple, quick, and low-cost and could inform safe labeling and use"
FDA-2024-P-3567-0001_Suitability_Petition_from_Lachman_Consulting_Servi.pdf,"July 25, 2024",,"Lachman Consulting Services, Inc.","A client represented by Lachman Consulting Services, Inc. (client identity not disclosed)",Section 505(j)(2)(C) of the FD&C Act; 21 C.F.R. § 10.20; 21 C.F.R. § 10.30,"FDA's lack of approval for lower strength (25 mg, 50 mg, 100 mg) sertraline capsules despite their utility for titration, initiation, and tapering of therapy","Declare that Sertraline Capsules, 25 mg, 50 mg, and 100 mg are suitable for submission in an Abbreviated New Drug Application (ANDA)","The currently approved capsule strengths (150 mg and 200 mg) do not accommodate initial titration or tapering; the proposed lower strengths would enhance dosing flexibility, improve patient adherence, reduce copays during titration, and align with approved labeling recommendations"
FDA-2024-P-3571-0001_Suitability_Petition_from_Premier_Consulting.pdf,"July 29, 2024",,"Premier Research Consulting, LLC",Premier Consulting is submitting on its own behalf; no separate represented entity is named,Section 505(j)(2)(C) of the FD&C Act; 21 CFR § 10.20; 21 CFR § 10.30; 21 CFR § 314.93,FDA’s current limitation of the Reference Listed Drug (LOTREL) to capsule dosage form only,Determine that Amlodipine and Benazepril hydrochloride Oral Liquid is suitable for submission in an Abbreviated New Drug Application (ANDA),"The proposed product differs only in dosage form (oral liquid vs. capsule) while maintaining the same active ingredients, indication, route, and dosing regimen as the RLD; this change facilitates administration, particularly for patients with swallowing difficulties, without introducing new safety or efficacy concerns"
FDA-2024-P-3573-0001_Suitability_Petition_from_Premier_Consulting.pdf,"July 29, 2024",,"Premier Research Consulting, LLC",Premier Consulting is submitting on its own behalf; no separate represented entity is named,Section 505(j)(2)(C) of the FD&C Act; 21 CFR § 10.20; 21 CFR § 10.30; 21 CFR § 314.93,FDA’s limitation of the Reference Listed Drug (ZESTORETIC) to tablet dosage form,Determine that Lisinopril and Hydrochlorothiazide Oral Liquid is suitable for submission in an Abbreviated New Drug Application (ANDA),"The proposed oral liquid formulation maintains the same active ingredients, dosage strengths, route of administration, and indication as the RLD ZESTORETIC; converting the dosage form from tablet to liquid facilitates administration, particularly in populations with swallowing difficulties, without introducing new safety or efficacy concerns"
FDA-2024-P-3699-0001_Citizen_Petition_from_Zydus_Pharmaceuticals__USA__.pdf,"August 2, 2024",,Zydus Pharmaceuticals (USA) Inc.,Zydus Pharmaceuticals (USA) Inc. is submitting on its own behalf; no separate represented entity is named,21 C.F.R. § 10.25(a); 21 C.F.R. § 10.30; 21 C.F.R. § 314.161; 21 C.F.R. § 314.122,"Whether IC-GREEN (indocyanine green for injection, USP) 25 mg has been withdrawn from sale for safety or effectiveness reasons",Request a determination from the FDA as to whether the Reference Listed Drug IC-GREEN 25 mg was withdrawn from sale for reasons of safety or effectiveness,IC-GREEN 25 mg is listed as discontinued in the FDA’s Orange Book and is no longer marketed by Renew Pharmaceuticals Ltd.; a determination is needed to clarify whether the discontinuation was due to safety or effectiveness concerns to support potential ANDA submission
FDA-2024-P-3761-0001_Citizen_Petition_from_Spark_Biomedical__Inc_.pdf,"July 31, 2024",,"Spark Biomedical, Inc.","Spark Biomedical, Inc. is submitting on its own behalf; no separate represented entity is named",Section 3060(a) of the 21st Century Cures Act; Section 201(h) of the FD&C Act,FDA’s lack of enforcement on neurostimulation wellness devices making unapproved medical claims,"Enforce regulation of neurostimulation wellness products making therapeutic claims, remove non-compliant products from the market, and require amended advertising to eliminate misleading medical claims",Neurostimulation wellness devices are being marketed with unsubstantiated claims about treating serious medical conditions without FDA approval; such devices should be regulated as medical devices under existing law to protect public health and ensure consumer safety
FDA-2024-P-3799-0001_Citizen_Petition_from_Raaha_LLC.pdf,"August 7, 2024",,Raaha LLC,Raaha LLC is submitting on its own behalf; no separate represented entity is named,Section 505(j)(2)(C) of the FD&C Act; 21 CFR § 10.20; 21 CFR § 10.30; 21 CFR § 314.92,Approval of ANDAs for Prednisolone Ophthalmic Solution 1% without demonstrating long-term stability under refrigerated conditions,"Require generic applicants to submit long-term stability studies under refrigerated conditions for Prednisolone Ophthalmic Solution 1%, withhold approval of ANDAs lacking such data, and reconsider approval and rating of ANDA #216935 if it lacks these studies","Refrigerated storage is permitted per the RLD labeling; ophthalmic suspensions are sensitive to temperature variations affecting critical quality attributes like particle size and viscosity; lack of stability data under refrigerated conditions could compromise product quality, safety, and efficacy, posing risks to public health"
FDA-2024-P-3820-0001_Citizen_Petition_from_Vanguard_Regulatory_Services.pdf,"August 9, 2024",,"Vanguard Regulatory Services, Inc.","Vanguard Regulatory Services, Inc. is submitting the petition on behalf of Nagase Viita Co., Ltd.","21 C.F.R. § 10.30; 21 C.F.R. § 101.9(c)(6)(i); Sections 403(q), 403(a), 201(n), and 701(a) of the FD&C Act",FDA’s current exclusion of Isomaltodextrin (IMD) from the definition of dietary fiber under 21 C.F.R. § 101.9(c)(6)(i),Amend the definition of dietary fiber in 21 C.F.R. § 101.9(c)(6)(i) to include Isomaltodextrin (IMD/Fibryxa®) as an isolated or synthetic non-digestible carbohydrate with beneficial physiological effects,"Scientific studies show that IMD significantly reduces postprandial blood glucose and triglyceride levels in humans, especially in individuals with elevated responses; thus, IMD provides beneficial physiological effects and meets the criteria for inclusion as a dietary fiber under FDA regulations"
FDA-2024-P-3821-0001_Cover_Letter_for_Suitability_Petition_from_Aurora_.pdf,"August 8, 2024",,"Aurora Pharmaceutical, Inc.","Aurora Pharmaceutical, Inc. is submitting on its own behalf; no separate represented entity is named","Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act",FDA’s current approval of Nexgard® (afoxolaner) Chewables as the reference listed new animal drug,"Request permission to submit an abbreviated new animal drug application (ANADA) for Afoxolaner Oral Solution 1.84% w/v, differing in dosage form from the reference listed drug",The proposed generic differs only in dosage form from Nexgard® chewables; Aurora seeks approval to proceed with an ANADA for afoxolaner in oral solution form under the suitability provisions of the FD&C Act
FDA-2024-P-3822-0001_Citizen_Petition_from_University_of_Illinois__Coll.pdf,"August 10, 2024",,"University of Illinois, College of Pharmacy","Submitted by Sarfaraz K. Niazi, Ph.D., on behalf of the University of Illinois, College of Pharmacy",The Biologics Price Competition and Innovation Act (BPCIA); 42 USC 262(k); 21 C.F.R. § 10.30,"FDA's prohibition against the U.S. Pharmacopeia (USP) creating monographs for biological drugs, specifically banning side-by-side analytical testing of biosimilars","Rescind FDA’s directive to the USP prohibiting the development of monographs for biological drugs, and allow USP to create Biological Product Specifications (BPS) that define release specifications for biosimilars","Creating BPS would eliminate the need for costly side-by-side analytical testing with the reference product, reduce development costs, facilitate broader biosimilar access, promote harmonization, and enhance global regulatory acceptance while maintaining safety and efficacy"
FDA-2024-P-3881-0001_Suitability_Petition_from_Zydus_Pharmaceuticals__U.pdf,"August 13, 2024",,Zydus Pharmaceuticals (USA) Inc.,Zydus Pharmaceuticals (USA) Inc. is submitting on its own behalf; no separate represented entity is named,Section 505(j)(2)(C) of the FD&C Act; 21 C.F.R. § 314.93; 21 C.F.R. §§ 10.20 and 10.30,FDA’s current limitation of the approved strengths of NUPLAZID (pimavanserin) Tablets to 10 mg and 17 mg,"Determine that Pimavanserin Tablets, 34 mg, is suitable for submission in an Abbreviated New Drug Application (ANDA)","The 34 mg strength matches the recommended daily dose stated in the RLD prescribing information; offering this strength in tablet form will enhance prescribing flexibility without changing dosage form or regimen, and does not raise new safety or efficacy concerns"
FDA-2024-P-3905-0001_Suitability_Petition_from_Lachman_Consulting_Servi.pdf,"August 15, 2024",,"Lachman Consulting Services, Inc.","Lachman Consulting Services, Inc. submitted the petition on behalf of an undisclosed client",Section 505(j)(2)(C) of the FD&C Act; 21 C.F.R. § 10.20; 21 C.F.R. § 10.30,"FDA’s existing approval of Estrace® Vaginal Cream, 0.01%, as the reference listed drug, and the dosage form limitation to cream","Determine that Estradiol Vaginal Inserts, 1 g and 2 g, are suitable for submission in an Abbreviated New Drug Application (ANDA)","The proposed vaginal inserts match the active ingredient and strength of the RLD cream but offer a pre-measured, easier-to-administer alternative that avoids waste and variability due to patient handling; this dosage form benefits patients with limited dexterity or vision and aligns with current dosing recommendations"
FDA-2024-P-3997-0001_Citizen_Petition_from_Aylstock__Witkin__Kreis___Ov.pdf,"August 20, 2024",,"Aylstock, Witkin, Kreis & Overholtz, PLLC",The firm submitted the petition on its own behalf but discloses representation of consumers who purchased BPO products contaminated with benzene,21 C.F.R. § 10.30; 21 C.F.R. § 330.10(a)(12); 21 C.F.R. § 330.10(b); Section 501(a)(2)(B) of the FD&C Act,FDA’s continued allowance of benzoyl peroxide (BPO) drug products on the market despite benzene contamination,Recall and suspend sales of all benzoyl peroxide (BPO) products from the U.S. market due to the presence of benzene at levels deemed unsafe by FDA standards,"Independent lab testing showed widespread and significantly high levels of benzene in various BPO products; benzene is a Class 1 carcinogen, and its presence at levels exceeding 2 ppm violates FDA and international safety limits; the FDA has previously determined such levels to pose life-threatening risks and warrant recalls"
FDA-2024-P-4015-0001_Citizen_Petition_from_Kohl_Harrington_Redacted.pdf,"August 22, 2024",,Kohl Harrington,Kohl Harrington is submitting on his own behalf; no separate represented entity is named,5 U.S.C. § 552 (Freedom of Information Act); 21 C.F.R. § 10.30(b); 21 C.F.R. §§ 25.30 and 25.34,FDA-CVM’s failure to publicly post calendar records of employee Charlotte Conway despite likely being subject to multiple FOIA requests,"Comply with FOIA by posting calendar records for FDA-CVM employee Charlotte Conway (covering July 1–31, 2024) on the FDA FOIA Reading Room website",The FOIA requires agencies to publicly post records requested three or more times or likely to be requested again; failure to do so violates statutory obligations and undermines transparency
FDA-2024-P-4126-0001_Suitability_Petition_from_Aurora_Pharmaceutical__I.pdf,"August 28, 2024",,"Aurora Pharmaceutical, Inc.","Aurora Pharmaceutical, Inc. is submitting on its own behalf; no separate represented entity is named","Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. § 25.30(h); 21 C.F.R. § 25.15",FDA’s current approval of Metacam® (meloxicam) Oral Suspension in 0.5 mg/mL and 1.5 mg/mL strengths as the reference listed new animal drug (RLNAD),"Allow submission of an ANADA for Meloxicam Oral Solution 3 mg/mL, a higher strength and different dosage form intended for dogs over 10 lbs.","The proposed solution offers improved dosing accuracy and ease of administration for large dogs compared to the current suspension that requires shaking; the higher concentration reduces dosing volume, enhancing compliance without compromising safety based on prior toxicology data"
FDA-2024-P-4134-0001_Suitability_Petition_from_Pharmobedient_Consulting.pdf,"August 24, 2024",,"Pharmobedient Consulting, LLC","Pharmobedient Consulting, LLC is submitting on its own behalf; no separate represented entity is named","Section 505(j)(2)(C) of the FD&C Act; 21 C.F.R. §§ 10.20, 10.30, 314.93; 21 C.F.R. § 25.31",FDA’s current limitation of approved Diclofenac Potassium tablet strengths to 25 mg and 50 mg,"Determine that Diclofenac Potassium Tablets, 37.5 mg, is suitable for submission in an Abbreviated New Drug Application (ANDA)","The 37.5 mg strength offers physicians greater dosing flexibility, enabling individualized treatment plans and lower effective dosing options; it remains bioequivalent to existing strengths and introduces no new concerns of safety or efficacy"
FDA-2024-P-4135-0001_Suitability_Petition_from_Fresenius_Kabi_USA__LLC.pdf,"August 27, 2024",,"Fresenius Kabi USA, LLC","Fresenius Kabi USA, LLC is submitting on its own behalf; no separate represented entity is named",Section 505(j)(2)(C) of the FD&C Act; 21 C.F.R. § 314.93; 21 C.F.R. §§ 10.20 and 10.30,FDA’s current approval of Vasopressin in 0.9% Sodium Chloride Injection only in 20 units/100 mL and 40 units/100 mL strengths,"Determine that Vasopressin in 0.9% Sodium Chloride Injection, 50 units/50 mL (1 unit/mL) in a single-dose ready-to-use container is suitable for submission in an Abbreviated New Drug Application (ANDA)","The proposed 1 unit/mL strength aligns with dosing in the approved labeling, reduces the number of IV bags needed for high-dose administrations, supports fluid-restricted patients, and complies with ASHP standards for standardized concentrations; it introduces no new safety or efficacy concerns and matches therapeutic expectations of the reference listed drug"